Chapter 080. Cancer Cell Biology and Angiogenesis (Part 4) ppsx

Cancer Cell Biology and Angiogenesis Part 4 Telomerase DNA polymerase is unable to replicate the tips of chromosomes, resulting in the loss of DNA at the specialized ends of chromosom

Chapter 080 Cancer Cell Biology

and Angiogenesis

(Part 4)

Telomerase

DNA polymerase is unable to replicate the tips of chromosomes, resulting

in the loss of DNA at the specialized ends of chromosomes (called telomeres) with

each replication cycle At birth, human telomeres are 15- to 20-kb pairs long and are composed of tandem repeats of a six-nucleotide sequence (TTAGGG) that associate with specialized telomere-binding proteins to form a T-loop structure that protects the ends of chromosomes from being mistakenly recognized as damaged The loss of telomeric repeats with each cell division cycle causes

gradual telomere shortening, leading to growth arrest (called replicative

senescence) when one or more critically short telomeres triggers a p53-regulated

DNA-damage checkpoint response Cells can bypass this growth arrest if pRB and

p53 are nonfunctional, but cell death ensues when the unprotected ends of chromosomes precipitate chromosome fusions or other catastrophic DNA

rearrangements (termed crisis) The ability to bypass telomere-based growth

limitations is thought to be a critical step in the evolution of most malignancies

This occurs by the reactivation of telomerase expression in cancer cells Telomerase is an enzyme that adds TTAGGG repeats onto the 3' ends of chromosomes It contains a catalytic subunit with reverse transcriptase activity (hTERT) and an RNA component that provides the template for telomere extension Most normal somatic cells do not express sufficient telomerase to prevent telomere attrition with each cell division Exceptions include stem cells (such as those found in hematopoietic tissues, gut and skin epithelium, and germ cells) that require extensive cell division to maintain tissue homeostasis More than 90% of human cancers express high levels of telomerase that prevent telomere exhaustion and allow indefinite cell proliferation In vitro experiments indicate that inhibition of telomerase activity leads to tumor cell apoptosis Major efforts are underway to develop methods to inhibit telomerase activity in cancer cells The reverse transcriptase activity of telomerase is a prime target for small-molecule pharmaceuticals The protein component of telomerase (hTERT) can act

as a tumor-associated antigen recognized by antigen-specific cytotoxic T lymphocytes (CTL) that lyse human melanoma, prostate, lung, breast, and colon cancer cells in vitro Clinical trials of telomerase vaccines are underway

Signal Transduction Pathways as Therapeutic Targets in Cancer Cells

Since the discovery that the v-src oncogene has protein tyrosine kinase

activity, the central role of tyrosine phosphorylation in cellular responses to growth factors has become apparent Many tyrosine kinases act at the apex of signaling pathways and are transmembrane proteins (receptor tyrosine kinases,

RTK) or are associated with structures at the plasma membrane (Src-, Janus-, and

Fak-family kinases) RTKs are transmembrane glycoproteins that undergo

dimerization upon ligand binding, with activation of their cytoplasmic tyrosine kinase domains by proximity-induced trans-phosphorylation of the activation loop Tyrosine residues of the receptor or adaptor proteins (such as IRS-1 or Shc) are phosphorylated and act as docking sites for proteins containing SH2 (Src-homology 2) or PTB (phosphotyrosine binding) domains, thus initiating multiple signal transduction pathways (Fig 80-2) Normally, tyrosine kinase activity is short-lived and reversed by protein tyrosine phosphatases (PTP) However, in many human cancers, tyrosine kinases or components of their downstream pathways are activated by mutation, gene amplification, or chromosomal translocations Because these pathways regulate proliferation, survival, migration, and angiogenesis, they have been identified as important targets for cancer therapeutics

Figure 80-2

Therapeutic targeting of signal transduction pathways in cancer cells

Three major signal transduction pathways are activated by receptor tyrosine kinases (RTK) 1 The protooncogene Ras is activated by the Grb2/mSOS guanine nucleotide exchange factor, which induces an association with Raf and activation

of downstream kinases (MEK and ERK1/2) 2 Activated PI3K phosphorylates the membrane lipid PIP2 to generate PIP3, which acts as a membrane-docking site for

a number of cellular proteins including the serine/threonine kinases PDK1 and Akt PDK1 has numerous cellular targets including Akt and mTOR Akt phosphorylates target proteins that promote resistance to apoptosis and enhance cell cycle progression, while mTOR and its target p70S6K upregulate protein synthesis to potentiate cell growth 3 Activation of PLC-γ leads the formation of

diacylglycerol (DAG) and increased intracellular calcium, with activation of multiple isoforms of PKC and other enzymes regulated by the calcium/calmodulin system Other important signaling pathways involve non-RTKs that are activated

by cytokine or integrin receptors Janus kinases (JAK) phosphorylate STAT (signal transducer and activator of transcription) transcription factors, which translocate to the nucleus and activate target genes Integrin receptors mediate cellular interactions with the extracellular matrix (ECM), inducing activation of FAK (focal adhesion kinase) and c-Src, which activate multiple downstream pathways, including modulation of the cell cytoskeleton Many activated kinases and transcription factors migrate into the nucleus where they regulate gene transcription, thus completing the path from extracellular signals, such as growth factors, to a change in cell phenotype, such as induction of differentiation or cell proliferation The nuclear targets of these processes include transcription factors (e.g., Myc, AP-1, and serum response factor) and the cell cycle machinery (CDKs and cyclins) Inhibitors of many of these pathways have been developed for the treatment of human cancers Examples of inhibitors that are currently being evaluated in clinical trials are shown in purple